NZ's Fisher and Paykel rises; Morgan Stanley sees tariffs as key focus ahead of annual results

Shares of New Zealand's Fisher & Paykel Healthcare Corp FPH.NZ up 1% at NZ$36.53

The medical equipment maker to report FY25 results on Wednesday

Morgan Stanley expects FY26 NPAT forecast of NZ$422 million ($253.16 million) vs Visible Alpha estimate of NZ$426 million

Brokerage says FY26 forecasts imply limited gross margin expansion due to expected U.S. tariff impacts on products manufactured in New Zealand

MS to focus on impacts from most recent U.S. flu season and trends for new applications growth in co's hospitals segment

Brokerage also looking for co's updates on newer mask launches and commentary on potential impact of GLP-1s on the obstructive sleep apnea (OSA) market

Stock rated "equal-weight" with a price target of NZ$36.7

Fisher & Paykel down 5.1% YTD, including current session's moves

($1 = 1.6669 New Zealand dollars)